
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a promising biotech company with a strong portfolio of approved and pipeline drugs, focusing on the treatment of various cancers. The company's flagship drug Brukinsa is a significant revenue generator, with two other commercialized drugs in their portfolio. With a global presence and a strong focus on research and development, BeOne Medicines has the potential for significant growth and success in the future.
Bears say
BeOne Medicines is facing intense competition in the oncology therapeutics market from established players such as AbbVie and AstraZeneca. While the company's flagship product, Brukinsa, has shown promising results and contributed significantly to the company's revenue, its other two drugs generate revenue mainly from China, posing a risk of over-reliance on the Chinese market. The company's pipeline of over 50 drugs in clinical trials could potentially diversify its revenue streams in the long term, but it remains to be seen if these drugs will achieve regulatory approval and commercial success. Overall, the company's dependence on a single product and its heavy focus on the Chinese market are reasons for a negative outlook on its stock.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares